Cell4Cure appoints Professor Leif Salford, one of the inventors behind the company’s proprietary technology platform as its Senior Advisor

Solna, Sweden, 2 February 2024, Cell4Cure AB - A Swedish private ATMP company working with antigen-specific dendritic cell mediated tolerance, aiming for curing disease where the immune system has become the enemy - today announced that they have appointed Dr Leif Salford, former Professor of Neurosurgery at Lund University, former Head of the Department of Neurosurgery, Lund University Hospital, as its Senior Advisor.

​

Salford started his research on hypoxia and ischemia in the rat brain at the Department of Neurosurgery, Lund University, Sweden and at Cornell University New York 1970-74. Salford set up the Translational Neuro-Oncology Laboratory in the Department of Neurosurgery, Lund, Sweden, in 1977 to seek a cure for the 100 per cent fatal brain tumor malignant glioma.

When the technology was to be transferred to the clinical phase, the Rausing family stepped in with substantial financial support, giving the laboratory its new name. After 2 years in Kuwait where Leif supported the building of a medical faculty, he returned to Lund as chief physician at the Neurosurgeon and ran the Rausing laboratory. A Professorship was obtained in Neurosurgery in Lund in 1996 and Salford continued to work as head of Neurosurgery until 2008. From 2009 to 2018, Leif Salford worked as senior professor and continued as head of the Rausing laboratory. In collaboration with Bengt Widegren and Hans-Olov Sjögren, professors of immunology, dendritic cells came into the picture and thus the focus and intense research on therapies against the autoimmune diseases also arose. This work was continued within a new company, Idogen AB, founded by the researchers in 2008.

Professor Leif Salford: “This technology platform started off through my past research in glioma, a severe type of brain cancer, performed at the Rausing laboratory. There we investigated the possibility of making dendritic cells to be an integral part of creating an effective treatment against auto immune diseases. I am now extremely happy that our grand and complicated idea since many years has translated into a platform for creating antigen specific tolerance. 

Going forwarding, in my role as Senior Advisor, I hope to support Cell4Cure's continued work aiming for more effective treatments for our patients. This feels very honoring and meaningful since, as a former clinician, I know that healthcare still faces major challenges.”

Christina Herder, CEO: “I am delighted to have Leif Salford as our advisor. Cell4Cure’s progress will highly depend on our valuable academic and clinical network, and Leif is definitely one of the important ones.”

Agneta Edberg, co.founder and chair: “Leif’s knowledge and wholehearted dedication is a truly valuable part of our platform legacy. I am so glad to have him on our team supporting us with his extensive knowledge, network and energy. I would also like to reach out and honor his fellow co-workers helping out in the past, by expressing our thanks and our gratitude for this future possibility.”

For more information, please contact;

Christina Herder, CEO

Telephone: +46 703747156

E-mail: christina.herder@cell4cure.com

About Cell4Cure

Cell4Cure AB is a Swedish, privately held cell therapy company committed to the development of treatments for inducing of immune tolerance. The company’s proprietary technology platform is based on dendritic cells mediating antigen-specific tolerance for the prevention or cure of diseases where the immune system is the enemy.

The company’s first clinical study, Toler8, is focusing on inducing tolerance to FVIII thereby preventing the occurrence of FVIII inhibitors, i.e. neutralizing antibodies, in hemophilia A patients.

Cell4Cure will as a first step deliver value to patients and shareholders by advancing this program to clinical proof of concept.

For more information visit www.cell4cure.com.

​

​

​